Target intelligence / Profile preview

Rotavirus VP7 glycoprotein (VP7)

Target
VP7
Molecular classification
Viral structural protein, Glycoprotein, Outer capsid protein, Other
01

Overview

The **Rotavirus VP7 glycoprotein** is a highly conserved structural protein forming the outermost layer of the rotavirus capsid[4][8]. It is a trimeric, calcium ion–stabilized glycoprotein synthesized and processed in the endoplasmic reticulum, where it is essential for virion assembly and stability[1][4]. VP7 is the principal target of neutralizing antibodies, making it a primary determinant of rotavirus G serotypes and a critical antigen for vaccine development[3][5][6]. Removal of Ca2+ ions destabilizes the VP7 trimer and initiates viral entry by promoting uncoating[3][5]. VP7 contains multiple neutralizing epitopes and is subject to antigenic variation, with its gene (segment 9) used for molecular classification of rotavirus strains[4][6]. The protein's proper folding and function require glycosylation and correct disulfide bond formation[7]. VP7-directed immune responses are central to both natural immunity and vaccine-mediated protection against rotavirus infection[3][6].

Other names
Rotavirus VP7VP7 proteinRotavirus outer-layer protein VP7
02

Mechanism of action

Neutralization: Antibodies stabilize the VP7 trimer, inhibiting uncoating and viral entry[3][5]. Induction of protective immunity: Subunit or inactivated vaccines based on VP7 elicit neutralizing antibodies[3].

03

Biological functions

Structural component of virionAssembly of viral outer capsidAntigenic determinant/immune response elicitorMediates capsid stability (Ca2+-stabilized trimer formation)Participates in virus entry and uncoating
04

Disease associations

Infection (central to rotavirus gastroenteritis)Other
05

Safety considerations

Antigenic variation due to sequence diversity in VP7 genotypes may impact vaccine efficacy[6]Potential for incomplete protection across rotavirus genotypes (immunological escape)[6]
06

Interacting drugs

Neutralizing monoclonal antibodies (e.g., 4F8)

1 more in the full profile.

07

Biomarkers

VP7-specific neutralizing antibodies can serve as biomarkers of exposure and immune response[3][6]

Beyond the preview

Go deeper on Rotavirus VP7 glycoprotein (VP7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rotavirus VP7 glycoprotein (VP7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call